Pharmaceutical

CHMP recommends AbbVie’s Rinvoq be approved for adult GCA

The CHMP has recommended the approval of AbbVie's upadacitinib (Rinvoq) for treating adults with giant cell arteritis (GCA).

Mar 1, 2025 - 06:00
CHMP recommends AbbVie’s Rinvoq be approved for adult GCA
The CHMP has recommended the approval of AbbVie's upadacitinib (Rinvoq) for treating adults with giant cell arteritis (GCA).
Read the original article

Tags:

Previous Article

Inborn errors of metabolism elicit unique challenges for therapy development

Next Article

Rare disease treatments skipping UK patients largely due to costs, survey shows

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Obesity market to reach $173.5 billion by 2031

Obesity market to reach $173.5 billion by 2031

Feb 11, 2025

STAT+: Biden’s SOTU highlights pharma’s biggest political problem: It is terrifyingly, awfully alone

STAT+: Biden’s SOTU highlights pharma’s biggest politic...

Mar 8, 2024

Denmark’s HTA evolution

Denmark’s HTA evolution

Dec 17, 2024